We are live on ! Find out more
STAB

Statera Biopharma, Inc. Common Stock
STAB

Delisted

STAB was delisted on the 11th of January, 2023.

Back to rankings

17 hedge funds and large institutions have $1.07M invested in Statera Biopharma, Inc. Common Stock in 2020 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

57% more capital invested

Capital invested by funds: $679K → $1.07M (+$390K)

0% more funds holding

Funds holding: 17 → 17 (0)

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

Holders
17
Holders Change
–
Holders Change %
0%
% of All Funds
0.35%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
3
Reduced
1
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Barclays
Barclays
United Kingdom
+$80.3K
2
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$9.03K
3
Wells Fargo
Wells Fargo
California
+$768
4
AIC
Archer Investment Corporation
Indiana
+$542
5
TRCT
Tower Research Capital (TRC)
New York
+$256

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$29.1K
2
WS
Wedbush Securities
California
-$22K
3
Citadel Advisors
Citadel Advisors
Florida
-$20K
4
Victory Capital Management
Victory Capital Management
Texas
-$2K
Name Holding Trade Value Shares
Change 		Change in
Stake
Renaissance Technologies
1
Renaissance Technologies
New York
$702K -$29.1K -16,100 -6%
Vanguard Group
2
Vanguard Group
Pennsylvania
$135K – – –
Barclays
3
Barclays
United Kingdom
$114K +$80.3K +44,450 New
Geode Capital Management
4
Geode Capital Management
Massachusetts
$45K – – –
BRWA
5
B. Riley Wealth Advisors
Florida
$44K – – –
Royal Bank of Canada
6
Royal Bank of Canada
Ontario, Canada
$22K +$9.03K +5,000 +138%
BlackRock
7
BlackRock
New York
$2K – – –
Carson Wealth (CWM LLC)
8
Carson Wealth (CWM LLC)
Nebraska
$2K – – –
Osaic Holdings
9
Osaic Holdings
Arizona
$1K – – –
Wells Fargo
10
Wells Fargo
California
$1K +$768 +425 +1,328%
AIC
11
Archer Investment Corporation
Indiana
$771 +$542 +300 New
FDCDDQ
12
Federation des caisses Desjardins du Quebec
Quebec, Canada
$257 – – –
WS
13
Wedbush Securities
California
– -$22K -13,321 Closed
Citadel Advisors
14
Citadel Advisors
Florida
– -$20K -12,009 Closed
Victory Capital Management
15
Victory Capital Management
Texas
– -$2K -1,410 Closed
Bank of America
16
Bank of America
North Carolina
– +$20 +11 +11%
TRCT
17
Tower Research Capital (TRC)
New York
– +$256 +142 New

STAB Hedge Fund Activity: Q2 2020 in Review

17 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Statera Biopharma, Inc. Common Stock (STAB) for Q2 2020, worth a combined $1.07M — up 57% from $679K a quarter earlier.

Fund positioning in STAB was balanced in Q2 2020: 3 funds opened new positions, 3 closed out, 3 added to existing stakes and 1 trimmed.

The largest buyer was Barclays, opening a new position worth an estimated $80.3K. The largest seller was Renaissance Technologies, cutting an estimated $29.1K.

  • 17 institutional investors held Statera Biopharma, Inc. Common Stock (STAB) as of Q2 2020, unchanged from Q1 2020.
  • Funds reported $1.07M of Statera Biopharma, Inc. Common Stock stock for Q2 2020, up 57% quarter-over-quarter.
  • 3 funds opened new Statera Biopharma, Inc. Common Stock positions in Q2 2020 and 3 closed out, a net change of 0 holders.
  • The largest Statera Biopharma, Inc. Common Stock buyer in Q2 2020 was Barclays, an estimated $80.3K added.
  • The largest Statera Biopharma, Inc. Common Stock seller in Q2 2020 was Renaissance Technologies, an estimated $29.1K sold.

Based on aggregated 13F filings for Q2 2020.